Description
calquence coupon
Calquence (acalabrutinib) is a targeted cancer treatment used for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL), in certain patients. calquence coupon
Calquence is a Bruton tyrosine kinase (BTK) inhibitor that works by blocking BTK, a protein that plays a key role in cancer cell growth and division. By inhibiting BTK, Calquence helps to slow the progression of cancer and helps extend patients’ lives
Calquence capsules and tablets are taken twice daily.
Calquence FDA approval was granted on October 31, 2017, for treating MCL. Its approval was later expanded to include CLL and SLL. Calquence is manufactured by AstraZeneca Pharmaceuticals.
What is Calquence used for?
Calquence is used for adult patients with:
- chronic lymphocytic leukemia (CLL)
- small lymphocytic lymphoma (SLL)
- mantle cell lymphoma (MCL) in patients
- are ineligible for autologous hematopoietic stem cell transplantation (HSCT), and calquence coupon
- used in combination with bendamustine and rituximab.
- who have received at least one prior therapy, or
- who are previously untreated, and
Reviews
There are no reviews yet.